A randomized, placebo-controlled, three-way crossover study to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2018
At a glance
- Drugs SCH 497079 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme
- 17 Dec 2008 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 17 Dec 2008 Status changed from recruiting to completed.
- 25 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by CT.gov